EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis

Zerong Wang, Xuelian Jin, Jiajia Zeng, Zilin Xiong, Xinchuan Chen

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05703-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2024. Verfasst von Zerong Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: West China Hospital, Sichuan University, Chendu, Sichuan, China. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Hematopoietic Stem Cell Transplantation, Janus Kinase Inhibitors, Nitriles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients’ symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisHematopoietic Stem Cell TransplantationJanus Kinase InhibitorsNitrilesPyrimidinesPyrazolesHumansAllograftsJanus Kinase 2Janus Kinase 1

Stichwörter der Autor:innen

Allogeneic hematopoietic stem cell transplantationGraft-versus-host diseaseJAK inhibitorsMyelofibrosisPoor implantationRuxolitinib

Substanzen

Janus Kinase InhibitorsNitrilesruxolitinibPyrimidinesPyrazolesJanus Kinase 2Janus Kinase 1

Autor:innen und Institutionen

  • West China Hospital, Sichuan University, Chendu, Sichuan, China.
  • West China Hospital, Sichuan University, Chendu, Sichuan, China. xinchuan_chen@163.com.

Zitieren

APA

Wang, Z., Jin, X., Zeng, J., Xiong, Z., & Chen, X. (2024). The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis. Annals of Hematology. https://doi.org/10.1007/s00277-024-05703-1

Vancouver

Wang Z, Jin X, Zeng J, Xiong Z, Chen X. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis. Annals of Hematology. 2024. doi:10.1007/s00277-024-05703-1

BibTeX
@article{Wang2024,
  author = {Wang, Zerong and Jin, Xuelian and Zeng, Jiajia and Xiong, Zilin and Chen, Xinchuan},
  title = {The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05703-1}
}
Kostenlos starten →